Adlai Nortye Ltd
ANL
Company Profile
Business description
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Contact
685 US Highway 1
New Jersey Biotechnology Development Center, 2nd floor
North BrunswickNJ08902
USAT: +1 848 230-7430
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
123
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,018.80 | 0.80 | -0.01% |
| CAC 40 | 8,149.50 | 18.65 | -0.23% |
| DAX 40 | 24,490.41 | 139.29 | 0.57% |
| Dow JONES (US) | 48,063.29 | 303.77 | -0.63% |
| FTSE 100 | 9,931.38 | 9.33 | -0.09% |
| HKSE | 25,630.54 | 224.06 | -0.87% |
| NASDAQ | 23,241.99 | 177.09 | -0.76% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,845.50 | 50.74 | -0.74% |
| S&P/ASX 200 | 8,714.30 | 0.50 | -0.01% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |